Buprenorphine
Buprenorphine is a partial opioid agonist used for opioid use disorder treatment and chronic pain.
About Buprenorphine
Buprenorphine is a partial mu-opioid receptor agonist also sold under brand names including Subutex, Sublocade, and Belbuca. It is primarily used to opioid Use Disorder Chronic Pain Management Medication Assisted Treatment Opioid Dependence. Buprenorphine is available in sublingual tablet (2 mg, 8 mg — subutex), buccal film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, 900 mcg — belbuca), transdermal patch (5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, 20 mcg/hr — butrans), subcutaneous extended-release injection (100 mg, 300 mg monthly — sublocade), and iv/im injection (0.3 mg/ml — buprenex) form. Healthcare providers commonly prescribe Buprenorphine for conditions including Attention Deficit Hyperactivity Disorder (ADHD).
Buprenorphine at a Glance
- Brand names
- Subutex, Sublocade, Belbuca
- Drug class
- Partial Mu-Opioid Receptor Agonist
- DEA schedule
- Schedule Schedule III (controlled substance)
- Pregnancy category
- FDA Category Category C — Buprenorphine has shown adverse effects in animal reproduction studies. Buprenorphine monotherapy is often preferred over the combination buprenorphine-naloxone product during pregnancy. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not promptly recognized and treated.
- Available forms
- Sublingual tablet (2 mg, 8 mg — Subutex), Buccal film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, 900 mcg — Belbuca), Transdermal patch (5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, 20 mcg/hr — Butrans), Subcutaneous extended-release injection (100 mg, 300 mg monthly — Sublocade), IV/IM injection (0.3 mg/mL — Buprenex)
- Therapeutic categories
- Addiction Medicine, Pain, Partial Opioid Agonist
- Conditions treated
- 1 related condition on this site
What Buprenorphine Is Used For
Dosage Quick Reference
These are general dosage guidelines for Buprenorphine. Your doctor will determine the appropriate dose for your specific situation.
| Condition | Starting Dose | Maintenance Dose |
|---|---|---|
| Opioid use disorder — induction (sublingual) | 2–4 mg on Day 1 once moderate withdrawal present | Titrate to 8–24 mg/day; target 16 mg/day for most patients |
| Opioid use disorder — extended-release (Sublocade) | 300 mg SC monthly × 2 months after sublingual stabilization | 100 mg SC monthly; may continue 300 mg if needed |
| Chronic pain (Belbuca buccal film) | 75 mcg every 12 hours (opioid-naive) | Titrate every 4 days; max 900 mcg every 12 hours |
| Chronic pain (Butrans patch) | 5 mcg/hr patch every 7 days | Titrate every 72 hours; max 20 mcg/hr |
| Acute moderate-to-severe pain (IV/IM) | 0.3 mg IV/IM every 6 hours as needed | Titrate to effect; monitor respiratory status |
Side Effects
Common Side Effects:
- Headache
- Nausea and vomiting
- Constipation
- Sweating
- Insomnia
- Pain
- Peripheral edema
- Sedation
- Application site reactions (patches)
Serious Side Effects:
- Respiratory depression
- Neonatal opioid withdrawal syndrome
- Hepatotoxicity
- Adrenal insufficiency
- QT prolongation
- Precipitated withdrawal
- Serotonin syndrome (with serotonergic drugs)
See also: Drug Interactions ↓
Drug Interactions
Buprenorphine carries serious interaction risks despite its partial agonist ceiling effect on respiratory depression.
- Benzodiazepines (e.g., alprazolam, clonazepam, diazepam): An FDA Boxed Warning highlights the risk of profound sedation, respiratory depression, coma, and death. Limit dose and duration if co-prescription is unavoidable, and counsel patients extensively.
- Other CNS depressants (alcohol, sedating antihistamines, gabapentin, pregabalin, sleep aids): Additive CNS and respiratory depression. Counsel patients to avoid alcohol entirely and disclose all sedating medications.
- CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): Increase buprenorphine plasma levels, potentially intensifying sedation. Monitor closely or reduce buprenorphine dose.
- CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): Accelerate buprenorphine metabolism, possibly precipitating withdrawal or loss of analgesia. Dose adjustment may be required.
- Full opioid agonists (e.g., morphine, oxycodone, fentanyl): Buprenorphine has very high mu-receptor affinity and may displace full agonists, precipitating acute withdrawal. Conversely, full agonists taken during buprenorphine therapy may have blunted analgesic effect.
- Serotonergic agents (SSRIs, SNRIs, MAOIs, triptans): May increase the risk of serotonin syndrome — monitor for agitation, hyperthermia, and clonus.
Key Considerations
Controlled substance
Buprenorphine is a Schedule Schedule III controlled substance under federal law. Prescriptions are regulated, refills may be restricted, and the medication has recognized potential for misuse or dependence. Use exactly as prescribed.
Known drug interactions
Buprenorphine has documented interactions with other medications, supplements, and certain foods. Review the Drug Interactions section below and tell your healthcare provider about every medication you take, including over-the-counter products. Jump to section →
Multiple forms available
Buprenorphine comes in more than one form (Sublingual tablet (2 mg, 8 mg — Subutex), Buccal film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, 900 mcg — Belbuca), Transdermal patch (5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, 20 mcg/hr — Butrans), Subcutaneous extended-release injection (100 mg, 300 mg monthly — Sublocade), IV/IM injection (0.3 mg/mL — Buprenex)). The right form for you depends on your condition, ease of use, and your provider's recommendation.
Additional Information
Buprenorphine is a partial opioid agonist used for the treatment of opioid use disorder and chronic pain management. This medication provides effective treatment for opioid dependence while having a unique pharmacological profile that limits its abuse potential and reduces overdose risk.
Mechanism of Action
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. As a partial agonist, it produces opioid effects (analgesia, euphoria) but with a ceiling effect—increasing doses beyond a certain point do not increase effects. This ceiling effect limits respiratory depression risk compared to full agonists. Buprenorphine has very high binding affinity for mu-receptors, allowing it to displace other opioids and prevent their effects. Its slow dissociation from receptors contributes to its long duration of action. The kappa antagonism may contribute to antidepressant effects and reduced dysphoria.
Available Formulations
Buprenorphine is available in multiple formulations: sublingual tablets (2 mg, 8 mg), buccal film, transdermal patch (for pain), extended-release subcutaneous injection (monthly), and implantable rods (lasting 6 months). For opioid use disorder, sublingual and injectable formulations are preferred. The sublingual tablet must dissolve under the tongue; swallowing reduces bioavailability to approximately 15%. Transdermal patches are used for chronic pain, not addiction treatment.
Medical Uses
Buprenorphine is FDA-approved for the treatment of opioid use disorder (OUD), moderate to severe chronic pain (transdermal patch), and acute pain severe enough to require opioid analgesia (buccal film). For OUD, it reduces cravings, prevents withdrawal symptoms, and blocks the effects of other opioids. Unlike methadone, qualified physicians can prescribe buprenorphine from office-based settings, improving treatment access. It is a preferred medication for opioid use disorder due to its safety profile and effectiveness.
Dosing Guidelines
For opioid use disorder using sublingual tablets, induction typically starts at 2-4 mg, with additional doses of 2-4 mg given at intervals until withdrawal symptoms are controlled (usually 8-16 mg on day 1). Maintenance doses typically range from 16-24 mg daily. For chronic pain using transdermal patches, the starting dose is typically 5 mcg/hour, applied weekly. Buprenorphine should be initiated when the patient is in mild to moderate opioid withdrawal to prevent precipitated withdrawal. Extended-release injectable formulations provide monthly or weekly dosing options.
Important Safety Information
Buprenorphine carries a boxed warning regarding serious, life-threatening respiratory depression, especially when used with benzodiazepines or other CNS depressants, and for neonatal opioid withdrawal syndrome when used during pregnancy. Precipitated withdrawal can occur if administered to patients physically dependent on full opioid agonists who are not in withdrawal. The medication is a Schedule III controlled substance. Hepatotoxicity has been reported. Orthostatic hypotension and QT prolongation may occur.
Drug Interactions
CNS depressants (benzodiazepines, alcohol, other opioids, sedatives) may cause profound sedation, respiratory depression, and death. CYP3A4 inhibitors (ketoconazole, ritonavir) may increase buprenorphine levels. CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may decrease levels. Buprenorphine can precipitate withdrawal in patients dependent on full opioid agonists. Naltrexone will block buprenorphine effects; adequate washout periods are required when switching between medications.
Special Populations
Buprenorphine use during pregnancy can cause neonatal opioid withdrawal syndrome; however, the benefits of treatment may outweigh the risks, and methadone or buprenorphine is recommended over discontinuation for pregnant women with opioid use disorder. Buprenorphine is excreted in breast milk; breastfeeding women on stable buprenorphine doses may breastfeed with monitoring. Safety in pediatric patients has not been established for OUD. Elderly patients may require lower doses. Severe hepatic impairment requires dose adjustment; the medication should be used with caution in moderate impairment.
Frequently Asked Questions
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.